The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Global pivotal Phase 3 trial will evaluate efficacy and safety of atebimetinib + modified gemcitabine/nab-paclitaxel (mGnP) compared to standard ...

View Immuneering Corp. Class A IMRX stock quote prices, financial information, real-time forecasts, and company news from CNN.

Immuneering says 100% suppression of acquired RAS alterations was observed in evaluable patients, supporting goal of Universal-RAS activity. Initial data from multiple arms of the Phase 2a portion of ...

Despite its CEO's enthusiasm, Immuneering's stock opened down 6% at $2.22. (akinbostanci/iStock/Getty Images Plus) Immuneering has reported 94% overall survival (OS ...

- Updated data for IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients show favorable overall response ...

Immuneering (NASDAQ:IMRX) operates at the intersection of biotechnology and data science, aiming to develop cancer drugs through a proprietary platform. Its central business is designing therapies, ...

Detailed price information for Immuneering Corp Cl A (IMRX-Q) from The Globe and Mail including charting and trades.

Immuneering Corporation announced Tuesday that it hired Harold “E.B.” Brakewood as its chief business officer. In the new role, Brakewood will lead corporate and business development as well as ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...